Navigation Links
UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
Date:12/5/2013

NEW YORK, Dec. 5, 2013 /PRNewswire/ -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased ARIAD Pharmaceuticals, Inc. ("ARIAD" or the "Company") (NASDAQ GS: ARIA) stock between December 12, 2011 and October 8, 2013. The Complaint alleges that throughout the Class Period defendants made false and misleading statements regarding the safety and efficacy of the leukemia drug Iclusig.

(Logo:  http://photos.prnewswire.com/prnh/20120409/MM84375LOGO)

For more information, click here: http://zlk.9nl.com/ariad-pharmaceuticals-aria.

On October 9, 2013, ARIAD announced that its leukemia drug Iclusig causes more side effects than previously reported; the Company also announced it would halt enrollment in its clinical trials and instruct current Iclusig users to lower their dosage. The Company disclosed that serious arterial thrombosis occurred in 11.8% of Iclusig-treated patients, and that 6.2% of the patients had cerebrovascular events. On this news, ARIAD shares declined $11.31 per share to close at $5.83 per share on October 9, 2013.

If you suffered a loss in ARIAD you have until December 9, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/ariad-pharmaceuticals-aria

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C.  The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:    
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com


'/>"/>
SOURCE Levi & Korsinsky, LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regeneron Announces Upcoming 2013 Investor Conference Presentation
2. Organovo Provides Guidance on Upcoming Retail Investor Conference
3. Ampio Pharmaceuticals to Present at Upcoming Investor Conference
4. Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2013
5. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
6. ViroPharma Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Alimera Sciences to Release Third Quarter 2013 Results and Provide Update on Upcoming FDA Advisory Committee Meeting
9. Epizyme, Inc. to Present at Upcoming Conferences in November
10. Volcano Announces Upcoming Data Presentations from Large-Scale Studies on Physiology and Imaging Technologies at TCT 2013
11. Healthcare Sector Announced Clinical Data Presentation, Upcoming Financial Release Schedules and Updates on New Drug Applications - Research Report on Alexion, Pacira, pSivida, Momenta and Impax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt ... the first patients in Nashville , ... the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) ... designed to provide long-term reflux control by restoring normal ... affects nearly 65 million people in the ...
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... , April 18, 2017 Research and ... Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at a ... report, Global Arthroscopy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... “The Saint ... Saint with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Dallas Metroplex where he works in the Dallas Independent School District teaching English. He ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a pre-clinical stage ... the treatment of Acute Ischemic Stroke (AIS), today announced it has appointed Creganna ... advances towards regulatory and clinical phases. , "This is another important step for ...
(Date:4/22/2017)... ... April 22, 2017 , ... Ecommerce sales have grown every year since ... $394.9 billion. The consequences of rapid innovation and growth are often neglected in ... it is every business and individual’s job to give something back to the planet ...
(Date:4/22/2017)... ... ... San Juan Capistrano summer camp team at the Boys and Girls Club of ... to provide physical activities for all campers. To read the report, click here ... increase in specialty camps that focus on what the report terms as “sitting subjects” like ...
(Date:4/21/2017)... Boston, MA (PRWEB) , ... April 21, 2017 ... ... Boston University professor Christopher Salas-Wright finds that youth violence is declining—and at noteworthy ... in the relative proportion of young people involved in violence in the United ...
Breaking Medicine News(10 mins):